Antisense therapy in cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Antisense oligodeoxynucleotides (ASOs) are short nucleic acid sequences designed to bind to specific messenger RNA (mRNA) molecules.
• This binding can modulate gene expression, offering a targeted approach to disease treatment.
• Their application in cancer therapy is an evolving field of research.

Purpose of the Study:

• To review the current state of laboratory and clinical research on antisense oligodeoxynucleotides (ASOs) for cancer treatment.
• To elucidate the mechanisms of action, pharmacokinetics, and toxicities associated with ASO therapeutics.
• To explore the potential clinical applications of ASOs in treating haematological malignancies and solid tumours.

Main Methods:

• Literature review of preclinical laboratory studies and clinical trials involving ASOs in oncology.
• Analysis of published data on ASO pharmacokinetics, including absorption, distribution, metabolism, and excretion.
• Examination of reported toxicities and adverse events from ASO administration in cancer patients.

Main Results:

• ASOs demonstrate diverse mechanisms of action against cancer cells, including mRNA degradation and modulation of protein translation.
• Pharmacokinetic profiles vary depending on ASO chemistry and delivery methods, impacting efficacy and duration of action.
• Clinical studies have shown varying degrees of success, with some ASOs progressing to later-stage trials for specific cancers.

Conclusions:

• Antisense oligodeoxynucleotides represent a promising therapeutic strategy for both haematological malignancies and solid tumours.
• Further research is needed to optimize ASO delivery, enhance efficacy, and manage potential toxicities for broader clinical adoption.
• The targeted nature of ASOs offers potential for personalized cancer medicine.